Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) serotypes are being tailored for numerous therapeutic applications, but the parameters governing the subcellular fate of even the most highly characterized serotype, AAV2, remain unclear. To understand how cellular conditions control capsid trafficking, we have tracked the subcellular fate of recombinant AAV2 (rAAV2) vectors using confocal immunofluorescence, three-dimensional infection analysis, and subcellular fractionation. Here we report that a population of rAAV2 virions enters the nucleus and accumulates in the nucleolus after infection, whereas empty capsids are excluded from nuclear entry. Remarkably, after subcellular fractionation, virions accumulating in nucleoli were found to retain infectivity in secondary infections. Proteasome inhibitors known to enhance transduction were found to potentiate nucleolar accumulation. In contrast, hydroxyurea, which also increases transduction, mobilized virions into the nucleoplasm, suggesting that two separate pathways influence vector delivery in the nucleus. Using a small interfering RNA (siRNA) approach, we then evaluated whether nucleolar proteins B23/nucleophosmin and nucleolin, previously shown to interact with AAV2 capsids, affect trafficking and transduction efficiency. Similar to effects observed with proteasome inhibition, siRNA-mediated knockdown of nucleophosmin potentiated nucleolar accumulation and increased transduction 5- to 15-fold. Parallel to effects from hydroxyurea, knockdown of nucleolin mobilized capsids to the nucleoplasm and increased transduction 10- to 30-fold. Moreover, affecting both pathways simultaneously using drug and siRNA combinations was synergistic and increased transduction over 50-fold. Taken together, these results support the hypothesis that rAAV2 virions enter the nucleus intact and can be sequestered in the nucleolus in stable form. Mobilization from the nucleolus to nucleoplasmic sites likely permits uncoating and subsequent gene expression or genome degradation. In summary, with these studies we have refined our understanding of AAV2 trafficking dynamics and have identified cellular parameters that mobilize virions in the nucleus and significantly influence AAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“Virus production. Virus was produced in HEK-293 cells as previously described ( 68 ).”
MethodSelf-citationFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 2×
“In general, it has proven difficult to discern whether infectious particles truly cross the nuclear membrane, due to the limitations of fluorescence microscopy (5, 67).”
BackgroundSelf-citationA Viral Phospholipase A2 Is Required for Parvovirus Infectivity
Zádori, Z., Szelei, J., Lacoste, M.-C., Li, Y., Gariépy, S., Raymond, P., Allaire, M., Nabi, I. R., & Tijssen, P. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00031-4 · Cited by 518
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 4×
“As previously reported, proteasome inhibitors and genotoxic agents affect events of subcellular processing to enhance transduction of rAAV2 in a cell type- and serotype-specific manner (16, 20, 27, 29).”
BackgroundInfluentialThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 3×
“A few groups have suggested that uncoating is not a rapid process for AAV2 (56, 61 , 75).”
BackgroundInfluentialGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 2×
“This impediment to gene delivery is exacerbated when particles lack VP1 or contain specific mutations in the unique N terminus of VP1 ( 23 ).”
BackgroundDouar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253 · cited 1×
“Beyond the barriers of the immune response (9, 42 ) and cell surface targeting (52), researchers are becoming increasingly aware that subcellular processing is a significant barrier to infection (16, 29, 52).”
Background
Cited by
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
“Empty AAV capsids, however, do enter target cells (24); thus, one limitation of our strategy is that increasing the capsid dose is likely to add to the total amount of capsid antigen being presented on MHC class I (13, 14) and contribute to the recognition of transduced cells by capsid-specific CD8+ T cells (1, 2, 11).”
BackgroundHastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Self-citationIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225
AAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Self-citationPharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
Adeno-Associated Virus Biology
Weitzman, M. D., & Linden, R. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_1 · Cited by 132
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Self-citationFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Popa-Wagner, R., Porwal, M., Kann, M., Reuss, M., Weimer, M., Florin, L., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00282-12 · Cited by 109
Earley, L. F., Powers, J. M., Adachi, K., Baumgart, J. T., Meyer, N. L., Xie, Q., Chapman, M. S., & Nakai, H. (2017) · Journal of Virology · doi:10.1128/jvi.01980-16 · Cited by 108
“Several studies have found a close association between nucleolar proteins and AAV2 capsids (27, 28), and it was found that AAV2 capsids are trafficked to the nucleolus following infection (29).”
BackgroundAdeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
“The authors go on to hypothesize that recruitment from the nucleoli into the nucleoplasm then facilitates uncoating of the viral genome in order to enable transcription of the recombinant genome [95] or, presumably, the integration or replication of wt AAV.”
BackgroundMitchell, A. M., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.01826-13 · Cited by 63
“We coadministered the drugs with 1,000 vector genomes per cell (vg/cell) rAAV2 to HeLa cells and compared their effects on transduction at 24 h (8).”
MethodResultSelf-citationAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61
Self-citationHighly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9
Tomono, T., Hirai, Y., Okada, H., Miyagawa, Y., Adachi, K., Sakamoto, S., Kawano, Y., Chono, H., Mineno, J., Ishii, A., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.015 · Cited by 55
Viral Single-Strand DNA Induces p53-Dependent Apoptosis in Human Embryonic Stem Cells
Hirsch, M. L., Fagan, B. M., Dumitru, R., Bower, J. J., Yadav, S., Porteus, M. H., Pevny, L. H., & Samulski, R. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027520 · Cited by 53
“Furthermore, previous work from our laboratory has demonstrated that empty AAV2 particles efficiently enter Hela cells and accumulate peri-nuclear, similar to the majority of genome containing capsids [19].”
BackgroundSelf-citationNicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Self-citationWang, Z., Lisowski, L., Finegold, M. J., Nakai, H., Kay, M. A., & Grompe, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.157 · Cited by 44
In Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH
Wang, S. K., Lapan, S. W., Hong, C. M., Krause, T. B., & Cepko, C. L. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.003 · Cited by 36
Mitchell, A. M., Li, C., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.03443-12 · Cited by 41
“Increased vector copy number is also observed with proteasome inhibition of AAV-transduced cells, which induces the nucleolar localization of rAAV2 (6); therefore, we investigated whether the effects of proteasome inhibition and As2O3 treatment on AAV2 transduction overlap.”
BackgroundResultInfluentialSelf-citationEfficient capsid antigen presentation from adeno-associated virus empty virions in vivo
Pei, X., Earley, L. F., He, Y., Chen, X., Hall, N. E., Samulski, R. J., & Li, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00844 · Cited by 35
“These results, based on the kinetics of capsid antigen presentation and the mechanism studies of capsid antigen presentation from AAV full particles and empty virions in vivo, are supported by the findings that AAV full particles can escape from endosomes and traffic to the nucleus more efficiently than empty virions…”
ResultSelf-citationQuantitative 3D Tracing of Gene-delivery Viral Vectors in Human Cells and Animal Tissues
Xiao, P.-J., Li, C., Neumann, A., & Samulski, R. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.250 · Cited by 33
Self-citationChaanine, A. H., Nonnenmacher, M., Kohlbrenner, E., Jin, D., Kovacic, J. C., Akar, F. G., Hajjar, R. J., & Weber, T. (2014) · Gene Therapy · doi:10.1038/gt.2014.7 · Cited by 25
The function of DNA binding protein nucleophosmin in AAV replication
Satkunanathan, S., Thorpe, R., & Zhao, Y. (2017) · Virology · doi:10.1016/j.virol.2017.07.007 · Cited by 24
Retina transduction by rAAV2 after intravitreal injection: Comparison between mouse and rat
Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0100-9 · Cited by 17
Metadata
- Authors
- Johnson, J. S., & Samulski, R. J.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2009-03-15
- Volume
- 83
- Issue
- 6
- Pages
- 2632-2644
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2066313345
- Cited by
- 162
- References
- 24
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.